US 11,427,544 · Application 16/302,021 · Granted Aug 30, 2022
US 11,427,544
Histone deacetylase 6 inhibitors and use thereof
Estimated expiration
May 16, 2037
10y 243d remaining
Earliest effective filing
May 16, 2017
+ 20 years
May 16, 2037
PTA +0d
May 16, 2037
No TD
—
Final
May 16, 2037
This calculation includes patent term adjustment (PTA) under 35 U.S.C. §154(b). Patent term extension (PTE) under 35 U.S.C. §156 (for FDA-regulated products) is not included.
Calculation details
Base term
- Filing date
- November 15, 2018
- Earliest effective filing
- May 16, 2017
- Issue date
- August 30, 2022
- PTA
- 0 days
- Base expiry (before PTA)
- May 16, 2037
May 16, 2017 + 20 years = May 16, 2037
- National stage entry of application PCTUS2017032784, filed May 16, 2017
- PRO62/336,863 — Provisional — not used for base term
- PRO62/336,863 — Provisional — not used for base term
Terminal disclaimers
Patent term extension under 35 U.S.C. §156, which can apply to certain drug, biologic, animal drug and medical device patents, is not included in this calculation. How PTE is calculated
The prosecution record for your AI
Application 16/302,021 · US 11,427,544
You have the date. Your AI can have the file.
PatentReply compiles the prosecution history behind US 11,427,544: the claims as filed and as allowed, every Office Action and response, and the cited references, with each answer pointing back to the filed passage.
One public application a month is free. The first compile takes a few minutes.
Strategy and filing changes require your approval.
Permanent link
www.patentreply.ai/tools/patent-expiration/US11427544Data sourced from public USPTO records. This tool provides informational estimates and should not be relied upon as legal advice. Always verify patent expiration dates independently, especially where patent term extension, terminal disclaimers, or unusual continuity issues may apply.